Related Experiment Video
Updated: May 12, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Triggers, bullets and targets, puzzle of membranous nephropathy
1Nephrology Department, Tabriz University of Medical sciences, Tabriz, IR Iran ; Mario NegriInstitute of Pharmacological Research, Bergamo, Italy.
Introduction:
Idiopathic Membranous Nephropathy (MN) is a common cause of adult nephrotic syndrome. Recently, M-type phospholipase A2 receptor (PLA2-R) has been discovered as the main podocyte antigen in the pathogenesis of idiopathic MN.
Materials And Methods:
In this mini review, the author searched English-language MEDLINE for the terms "membranous nephropathy", "rituximab", and "phospholipase A2 receptor" up to October 2011.
Results:
In support of its earlier discovery, reports from China and Europe confirmed the major pathogenic role of non-complement fixing IgG4 antibody against PLA2-R in the pathogenesis of idiopathic MN. Antibodies against aldose reductase (AR) and manganese superoxide dismutase (SOD2 ), and sub-epithelial deposition of cationic bovine serum albumin (BSA) are also reported in rare occasions. It seems that Rituximab is a good therapeutic choice for those patients who need immunosuppressive therapy.
Conclusions:
Great discoveries in the diagnosis and treatment of idiopathic MN have been performed but pathogenic mechanism and triggers for anti-PLA2-R production are still unknown.
Insights
Idiopathic Membranous Nephropathy (MN) is linked to the M-type phospholipase A2 receptor (PLA2-R). Rituximab shows promise as a treatment for MN patients requiring immunosuppression.
Area of Science:
- Nephrology
- Immunology
- Pathophysiology
Background:
- Idiopathic Membranous Nephropathy (MN) is a primary cause of nephrotic syndrome in adults.
- The M-type phospholipase A2 receptor (PLA2-R) is identified as the key podocyte antigen in MN pathogenesis.
- Recent findings highlight the pathogenic role of anti-PLA2-R antibodies.
Purpose of the Study:
- To review the literature on membranous nephropathy, rituximab, and PLA2-R.
- To summarize current understanding of PLA2-R's role in idiopathic MN.
- To evaluate rituximab as a therapeutic option for MN.
Main Methods:
- A mini-review of English-language MEDLINE literature.
- Search terms included "membranous nephropathy", "rituximab", and "phospholipase A2 receptor".
- Literature search conducted up to October 2011.
Main Results:
- Reports confirm the pathogenic role of IgG4 antibodies against PLA2-R in idiopathic MN.
- Rare cases involve antibodies against aldose reductase (AR) and manganese superoxide dismutase (SOD2).
- Rituximab is suggested as a viable therapeutic choice for immunosuppression in MN.
Conclusions:
- Significant advancements have been made in diagnosing and treating idiopathic MN.
- The precise pathogenic mechanisms and triggers for anti-PLA2-R antibody production remain undetermined.
More Related Videos
Related Concept Videos
Nephrotic Syndrome I : Introduction
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...
Nephrons
Diabetic Nephropathy
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

